MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Teriflunomide

Selected References:

  • Almas S, et al. 2016. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int:6527458. 
  • Amato MP and Portaccio E. 2015. Fertility, Pregnancy and Childbirth in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs. CNS Drugs 29:207-220. 
  • Andersen JB, et al. 2018. Pregnancy outcomes in men and women treated with teriflunomide. A population-based nationwide Danish registry study. Frontiers in Immunology 9(2706):1-7.
  • Aubagio® Prescribing Information. 12/2022. Available online at http://products.sanofi.us/aubagio/aubagio.pdf, accessed 12/2022.  
  • Barataud-Reilhac A, et al. 2020. Teriflunomide-exposed pregnancies in French cohort of patients with multiple sclerosis. Neurol Clin Pract 10(4): 287-297.  
  • Cree BA. 2013. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler.19:835-43.  
  • Chambers CD, et al. 2010. Birth outcomes in pregnant women taking leflunomide. Arthritis Rheu. 62(5):1494-503. 
  • Chambers C, et al. 2007. Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. Motherisk Update. 53(3):409-412. 
  • Cassina M, et al. 2012. Pregnancy outcome in women exposed to Leflunomide before or during pregnancy. Arth & Rheum 64(7):2085-2094. 
  • D’Aleo G, et al. 2020. Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient: A case report. Medicine (Baltimore) 99(28):e21212. 
  • Davenport L, et al. 2014. Teriflunomide: non-clinical evaluation demonstrates no effect on sperm DNA or male fertility [abstract]. Neurology 82(10 Supp):P2.233. 
  • De Santis M, et al. 2005. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis 64:1096-1097. 
  • Dobson R, et al. 2019. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol. 19:106–14 
  • Gold R and Wolinsky JS. 2011. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand 124(2):75-84. 
  • Henson LJ, et al. 2014. Updated pregnancy outcomes in patients and partners of patients in the terflunomide clinical trial program [abstract]. Neurology 82(10 Supp): P4.161. 
  • Kieseier B, et al. 2012. Pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database (Poster 737). Mult Scler;18(Suppl 4):328. 
  • Losee JE and Mason AC. 2005. Deformational plagiocephaly: diagnosis, prevention, and treatment. Clin Plastic Surg 31;53-64 
  • Lu E, et al. 2013. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Reviews 13(3):251-61. 
  • O’Connor P, et al. 2011: Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365(14):1293-1303.  
  • Varytė G, et al. 2021. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol 33(5):378-383. 
  • Vukusic  S, et al. 2020. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. Mult Scler 26(7):829-836.  
  • Weber-Schoendorfer C, et al. 2017. Leflunomide – A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. Reprod Toxicol 71:101-107. 

 

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.